Podcast Episodes
Back to Search
With unique license agreements in place with local universities and an additional $260M recently raised, Cambridge, UK based Apollo Therapeutics is building out a substantial pipeline
CEO Richard Mason describes the company's philosophy, and covers programs such as a FGF21/GLP-1 that was recently licensed from a Chinese partner, an…
1 year, 6 months ago
From Boston: Stifel Senior Analyst Paul Matteis talks about the orexin class of wakefulness medicines in development, and comments on recent news from companies he covers
He shares his take on biotech and discusses Alkermes, Tekada, Centessa, Jazz, Biogen, Stoke, Alnylam, BridgeBio, Xenon, and more.
1 year, 6 months ago
Australia based Aravax, which is using a peptide based approach to food allergy treatments with the goal of avoiding inflammation, is building out late stage manufacturing capabilities in Oxford, UK
CEO Pascal Hickey introduces us to the company and describes the scale up work Aravax is doing with vendors for its lead peanut allergy program, whil…
1 year, 6 months ago
Oxford based Theolytics is leveraging a library of 100M variants of adenoviruses for a bottom up approach to oncolytic virus cancer drug development
CEO David Apelian describes the importance of choosing the right strain for the right type of cancer, and discusses the company's lead program for ov…
1 year, 6 months ago
With three approved products and filings for more over the near term, Axsome's CEO describes the scale and reach this company is building in the CNS space
Herriot Tabuteau updates us on the commercialization of Auvelity and Sunosi, launch plans for the recently approved Symbravo, as well as numerous NDA…
1 year, 6 months ago
Stoke Therapeutics' CEO Ed Kaye discusses today's partnership news with Biogen on Zorevunersen for the treatment of Dravet syndrome
He describes the design of the global pivotal study, which will be initiating soon, why Stoke chose Biogen as a partner, and how today's non-dilutive…
1 year, 6 months ago
The CEO of Solid Biosciences discusses today's data release of the company's microdystrophin gene therapy candidate for Duchenne muscular dystrophy
Bo Cumbo describes the efficacy biomarkers and safety profile they are seeing, and explains why he believes the cascade of observations from microdys…
1 year, 6 months ago
Paula Brown Stafford, CEO of the global CRO Allucent, discusses how the company is purpose built to partner with mid-to-small sized biopharma companies on their success
Sponsored Content: She describes what appealed to her about Allucent when she took the CEO job in July of last year, and highlights the company's reg…
1 year, 7 months ago
Welcoming Ryan Flinn as BiotechTV's new 'AI in Biotech' contributor
Ryan is based in the Bay Area, and will will be covering AI news there on the ground and virtually worldwide for BiotechTV.
1 year, 7 months ago
Oppenheimer's Head of Healthcare Investment Banking shares his take on 2025 and highlights M&A, IPOs, and the ability of companies to raise money this year
Michael Margolis discusses the macro and policy factors that are in play this year, comments on the China factor, and describes how companies have be…
1 year, 7 months ago